General Information
Lurasidone is an orally administered substance that belongs to the class of atypical antipsychotic drugs (AAPD). These drugs are suggested to have less side effects in comparison to typical psychotic drugs. It is prescribed for the treatment of schizophrenia and bipolar depression ‘ specifically, for the treatment of depressive episodes associated with bipolar I disorder in adults when used alone or in combination with lithium or valproate. Lurasidone has been found to have a beneficial effect on cognitive performance in patients with acute psychosis. This suggests that lurasidone treatment may offer an approach for the prevention of cognitive impairment in individuals who are at risk for schizophrenia or related disorders involving cognitive impairment
About the API
- Japan DMF
- Korea DMF
- US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.